Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SRD5A2 as a Marker of Finasteride Resistance in BPH
NCT04288427Recruiting
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Sep 2020
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of finasteride in benign prostatic hyperplasia (BPH), sponsored by Beth Israel Deaconess Medical Center. Primary endpoint: American Urologic Association Symptom Index at 12 months. Started Sep 2020; status: recruiting.
02
Drugs
finasteride
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT04288427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04288427.